Controlling autoimmunity in sporadic inclusion-body myositis.
Steinman
Lawrence
L
Department of Neurology and Neurological Sciences, Beckman Center for Molecular Medicine, Stanford University, Stanford, CA 94305, USA. Steinman@stanford.edu
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001327:Autoimmune Diseases / Q000188:drug therapy*; D002634:Chemotaxis, Leukocyte / Q000187:drug effects; D006801:Humans; D006816:Huntington Disease / Q000378:metabolism / Q000473:pathology; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D002479:Inclusion Bodies / Q000737:chemistry / Q000276:immunology; D039041:Integrin alpha4beta1 / Q000037:antagonists & inhibitors; D008214:Lymphocytes / Q000502:physiology; D009132:Muscles / Q000473:pathology; D018979:Myositis, Inclusion Body / Q000188:drug therapy* / Q000473:pathology; D000069442:Natalizumab
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D039041:Integrin alpha4beta1; D000069442:Natalizumab